CStone Pharmaceuticals
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSPHF research report →
Price Chart
About the company
CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents.
- CEO
- Jianxin Yang
- IPO
- 2020
- Employees
- 136
- HQ
- Shanghai, SH, CN
Get TickerSpark's AI analysis on CSPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.12B
- P/E
- -21.86
- Fwd P/E
- 7.98
- PEG
- 0.16
- P/S
- 29.97
- P/B
- 10.88
- EV/EBITDA
- -26.07
- Div Yield
- 0.00%
- Gross Margin
- 39.88%
- Op Margin
- -120.09%
- Net Margin
- -123.30%
- ROE
- -64.78%
- ROIC
- -28.27%
Latest fiscal year · YoY change
- Revenue
- $262.63M-35.5%
- Gross Profit
- $44.79M-81.4%
- Op Income
- $-421,456,847
- Net Income
- $-425,725,766-366.8%
- EPS
- $-0.31-333.6%
- OCF Growth
- +4.5%
- FCF Growth
- +4.5%
- 52W High
- $1.01
- 52W Low
- $0.59
- 50D MA
- $0.67
- 200D MA
- $0.83
- Beta
- 0.25
- RSI (14)
- 50
- Avg Volume
- 4.15K
No earnings-call transcripts are available for CSPHF yet.
- Free Float
- 77.7%
- Shares Outstanding
- 1.60B
- Float Shares
- 1.24B
Our CSPHF coverage
Recent articles, reports, and earnings notes.
No research on CSPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSPHF report →CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
prnewswire.com · Jun 25
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
prnewswire.com · May 31
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
prnewswire.com · Apr 19
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
prnewswire.com · Mar 26
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
prnewswire.com · Mar 26
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
prnewswire.com · Feb 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.